156 related articles for article (PubMed ID: 11889175)
1. Functionally impaired TR mutants are present in thyroid papillary cancer.
Puzianowska-Kuznicka M; Krystyniak A; Madej A; Cheng SY; Nauman J
J Clin Endocrinol Metab; 2002 Mar; 87(3):1120-8. PubMed ID: 11889175
[TBL] [Abstract][Full Text] [Related]
2. Identification of naturally occurring dominant negative mutants of thyroid hormone alpha 1 and beta 1 receptors in a human hepatocellular carcinoma cell line.
Lin KH; Zhu XG; Shieh HY; Hsu HC; Chen ST; McPhie P; Cheng SY
Endocrinology; 1996 Oct; 137(10):4073-81. PubMed ID: 8828459
[TBL] [Abstract][Full Text] [Related]
3. Localization and expression of thyroid hormone receptors normal and neoplastic human thyroid.
Crescenzi A; Graziano MF; Carosa E; Papini E; Rucci N; Nardi F; Trimboli P; Calvanese A; Jannini EA; D'Armiento M
J Endocrinol Invest; 2003 Oct; 26(10):1008-12. PubMed ID: 14759075
[TBL] [Abstract][Full Text] [Related]
4. Expression of TRbeta1 mRNAs with functionally impaired mutations is rare in thyroid papillary carcinoma.
Takano T; Miyauchi A; Yoshida H; Nakata Y; Kuma K; Amino N
J Clin Endocrinol Metab; 2003 Jul; 88(7):3447-9. PubMed ID: 12843201
[TBL] [Abstract][Full Text] [Related]
5. Lack of mutations in the thyroid hormone receptor (TR) alpha and beta genes but frequent hypermethylation of the TRbeta gene in differentiated thyroid tumors.
Joseph B; Ji M; Liu D; Hou P; Xing M
J Clin Endocrinol Metab; 2007 Dec; 92(12):4766-70. PubMed ID: 17911173
[TBL] [Abstract][Full Text] [Related]
6. Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma.
Lin KH; Zhu XG; Hsu HC; Chen SL; Shieh HY; Chen ST; McPhie P; Cheng SY
Endocrinology; 1997 Dec; 138(12):5308-15. PubMed ID: 9389515
[TBL] [Abstract][Full Text] [Related]
7. Thyroid hormone receptor mutations in cancer.
Cheng SY
Mol Cell Endocrinol; 2003 Dec; 213(1):23-30. PubMed ID: 15062571
[TBL] [Abstract][Full Text] [Related]
8. Thyroid hormone receptors mutated in liver cancer function as distorted antimorphs.
Chan IH; Privalsky ML
Oncogene; 2006 Jun; 25(25):3576-88. PubMed ID: 16434963
[TBL] [Abstract][Full Text] [Related]
9. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
10. Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.
Hwang JH; Kim DW; Suh JM; Kim H; Song JH; Hwang ES; Park KC; Chung HK; Kim JM; Lee TH; Yu DY; Shong M
Mol Endocrinol; 2003 Jun; 17(6):1155-66. PubMed ID: 12637586
[TBL] [Abstract][Full Text] [Related]
11. Isoform-specific thyroid hormone receptor antibodies detect multiple thyroid hormone receptors in rat and human pituitaries.
Yen PM; Sunday ME; Darling DS; Chin WW
Endocrinology; 1992 Mar; 130(3):1539-46. PubMed ID: 1537303
[TBL] [Abstract][Full Text] [Related]
12. Dominant inhibition of thyroid hormone action selectively in the pituitary of thyroid hormone receptor-beta null mice abolishes the regulation of thyrotropin by thyroid hormone.
Abel ED; Moura EG; Ahima RS; Campos-Barros A; Pazos-Moura CC; Boers ME; Kaulbach HC; Forrest D; Wondisford FE
Mol Endocrinol; 2003 Sep; 17(9):1767-76. PubMed ID: 12819298
[TBL] [Abstract][Full Text] [Related]
13. Amino acid substitutions of thyroid hormone receptor-beta at codon 435 with resistance to thyroid hormone selectively alter homodimer formation.
Nomura Y; Nagaya T; Tsukaguchi H; Takamatsu J; Seo H
Endocrinology; 1996 Oct; 137(10):4082-6. PubMed ID: 8828460
[TBL] [Abstract][Full Text] [Related]
14. Isoform variable action among thyroid hormone receptor mutants provides insight into pituitary resistance to thyroid hormone.
Safer JD; Langlois MF; Cohen R; Monden T; John-Hope D; Madura J; Hollenberg AN; Wondisford FE
Mol Endocrinol; 1997 Jan; 11(1):16-26. PubMed ID: 8994184
[TBL] [Abstract][Full Text] [Related]
15. Aberrant localization of beta-catenin correlates with overexpression of its target gene in human papillary thyroid cancer.
Ishigaki K; Namba H; Nakashima M; Nakayama T; Mitsutake N; Hayashi T; Maeda S; Ichinose M; Kanematsu T; Yamashita S
J Clin Endocrinol Metab; 2002 Jul; 87(7):3433-40. PubMed ID: 12107263
[TBL] [Abstract][Full Text] [Related]
16. Dominant negative inhibition by mutant thyroid hormone receptors is thyroid hormone response element and receptor isoform specific.
Zavacki AM; Harney JW; Brent GA; Larsen PR
Mol Endocrinol; 1993 Oct; 7(10):1319-30. PubMed ID: 8264663
[TBL] [Abstract][Full Text] [Related]
17. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
Suzuki H; Zhang XY; Forrest D; Willingham MC; Cheng SY
Mol Endocrinol; 2003 May; 17(5):895-907. PubMed ID: 12576488
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
19. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
20. N-terminal variants of thyroid hormone receptor beta: differential function and potential contribution to syndrome of resistance to thyroid hormone.
Ng L; Forrest D; Haugen BR; Wood WM; Curran T
Mol Endocrinol; 1995 Sep; 9(9):1202-13. PubMed ID: 7491112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
